Parkinson Disease

FDA Approves New Pimavanserin Formulation, Dosage Strength

FDA Approves New Pimavanserin Formulation, Dosage Strength

By

Nuplazid, a non-dopaminergic, selective serotonin inverse agonist, targets 5-HT2A receptors that are thought to be involved in Parkinson's disease psychosis.

Enhanced Scale Helps Accurately Identify Psychotic Symptoms in Parkinson Disease

Enhanced Scale Helps Accurately Identify Psychotic Symptoms in Parkinson Disease

By

Using information from these assessments, investigators identified participants as having either major psychotic symptoms, isolated minor psychotic symptoms, or no psychotic symptoms.

Predictive Tool May Be Effective for Identifying Dementia Risk in Parkinson Disease

Predictive Tool May Be Effective for Identifying Dementia Risk in Parkinson Disease

By

Researchers conducted a multicenter study to assess the predictive value of the Montreal Parkinson Risk of Dementia Scale, an 8-item, office-based screening tool.

Prognostic Significance of Weight Loss in Patients With Early Parkinsonism

Prognostic Significance of Weight Loss in Patients With Early Parkinsonism

By

Investigators analyzed data for baseline factors that may influence weight loss in early parkinson's disease.

Sign Up for Free e-newsletters



CME Focus